



## **REGENXBIO to Host Conference Call on November 7 to Discuss Third Quarter 2018 Financial Results and Recent Operational Highlights**

October 31, 2018 8:05 PM EDT

ROCKVILLE, Md., Oct. 31, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV<sup>®</sup> Technology Platform, today announced that it will host a conference call on Wednesday, November 7, 2018 at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2018 and recent operational highlights.

To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international) and enter the passcode 8283205. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at [www.regenxbio.com](http://www.regenxbio.com). The recorded webcast will be available for approximately 30 days following the call.

### **About REGENXBIO Inc.**

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

### **CONTACT:**

#### **Investors**

Natalie Wildenradt, 646-681-8192  
[natalie@argotpartners.com](mailto:natalie@argotpartners.com)

#### **Media**

Adam Pawluk, 202-591-4063  
[apawluk@jpa.com](mailto:apawluk@jpa.com)



 View original content to download multimedia:<http://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-november-7-to-discuss-third-quarter-2018-financial-results-and-recent-operational-highlights-300740219.html>

SOURCE REGENXBIO Inc.